Baxter Acquires Synovis - To Consolidate its Position in the Soft Tissue Repair Market - Deal Analysis from GlobalData by GlobalData

VIEWS: 86 PAGES: 8

More Info
									                       C. R. Bard Acquires Lutonix - Set to Gain from a New
                           Technology - Deal Analysis from GlobalData
        Reference Code: GDME0044M&A                                                                                                                  Publication Date: January 2012


        1       Table of Contents
        1 Table of Contents.................................................................1
         1.1 List of Tables .................................................................1
         1.2 List of Figures ................................................................1
        2 Deal Summary .....................................................................2
         2.1 Transaction Details........................................................2
        3 Bard Acquires Lutonix - Set to Gain from a New Technology
          .............................................................................................2
         3.1 Deal Rationale ...............................................................2
           3.1.1         Growth Potential of the PTCA Drug-Eluting
                         Balloons Market ...................................................2
           3.1.2         C. R. Bard’s Inorganic Growth Strategy Led to the
                         Acquisition of Lutonix ...........................................3
           3.1.3         The Deal will Improve Bard’s Position in the
                         Cardiovascular Devices Market ............................4
         3.2 Company Profiles ..........................................................5
           3.2.1         C. R. Bard, Inc......................................................5
           3.2.2         Lutonix, Inc. ..........................................................6
        4 Appendix ..............................................................................6
         4.1 Research Methodology .................................................6
         4.2 Secondary Research .....................................................7
         4.3 Primary Research..........................................................7
         4.4 Models ...........................................................................7
         4.5 Forecasts.......................................................................7
         4.6 Expert Panels ................................................................7
         4.7 GlobalData Consulting ..................................................7
         4.8 Contact Us.....................................................................8
         4.9 Disclaimer......................................................................8



        1.1       List of Tables
        Table 1:        PTCA Drug-Eluting Balloons Market, Revenue ($m),
                        2010-2017 ................................................................2
        Table 2:        PTCA Drug-Eluting Balloons, Products ....................3
        Table 3:        Deals by C. R. Bard, 2004-2011 ...............................3
        Table 4:        C. R. Bard, Inc., Net Sales by Product Division, ($m),
                        2008-2010 ................................................................5
        Table 5:        C. R. Bard, Inc., Marketed Products .........................5



        1.2       List of Figures
        Figure 1: PTCA Drug-Eluting Balloons Market, Revenue ($m),
                  2010-2017 ................................................................2




                                                                                                                                                GDME0044M&A /Published JAN 2012/ Page 1
                                                                                                                                                                           Market Analysis Alert
C. R. Bard Acquires Lutonix - Set to Gain from a New Technology
                                                                                                           © GlobalData. This report is a licensed product and is not to be copied, reproduced,
                                                                                                                                                                   shared or resold in any form
        2     Deal Summary                                                           Figure 1:      PTCA Drug-Eluting Balloons Market, Revenue
                                                                                                    ($m), 2010-2017
        C. R. Bard, (Bard) acquired Lutonix, Inc. for a purchase
        consideration of $225m, plus an additional $100m to be paid                      120

        upon Pre-Market Approval (PMA) of Lutonix's product, Moxy.
                                                                                         100
        Bard is engaged in the development, manufacture and
                                                                                                            CAGR (2010-2017): 8.6%
        marketing of medical technologies in the areas of vascular,                       80

        urology, oncology and surgical specialty products. Lutonix is
        focused on the development and commercialization of drug-                         60

        coated balloon angioplasty technology through its product,
        Moxy. Following the acquisition, Bard expects to begin selling                    40

        the device in Europe in the second half of 2012. It has already
                                                                                          20
        received Conformité Européenne (CE) mark approval. It also
        plans to begin a larger registry study concurrent with the
                                                                                           0
        European launch to support broader marketing claims and                                             2010                              2017
        obtain additional clinical data.
                                                                                     Source: GlobalData, Annual Reports, SEC Filings, Investor Presentations,
        The acquisition of Lutonix is part of Bard’s strategy to gradually           Earning Call Transcripts, News and Press Releases, Scientific Journals, Trade
        strengthen its business operations and gain from Lutonix’s                   Associations, Interviews with Industry Experts and Key Opinion Leaders (KOLs)
        presence in the Peripheral Transluminal Coronary Angioplasty
        (PTCA) drug-eluting balloons market.
                                                                                     Table 1:     PTCA Drug-Eluting Balloons Market, Revenue
        2.1     Transaction Details                                                               ($m), 2010-2017
        C. R. Bard has acquired Lutonix, which is backed by a number                 Market Segment                                          2010               2017
        of ven
								
To top